Acute Porphyria Drug Database

J07CA06 - Diphtheria-Haemophilus Influenzae B-Pertussis-Poliomyelitis-Tetanus
Propably not porphyrinogenic
PNP

Rationale
Based on the pharmacokinetics of the diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus vaccine (DTP-IPV-Hib), there are no conceivable porphyrinogenic effects.
Chemical description
Diphtheria Toxoid, Tetanus Toxoid, Pertussis Toxoid, inactivated poliovirus (type 1,2 and 3) and Haemophilus influenzae Type b Polysaccharide (DTP-IPV-Hib)
Therapeutic characteristics
The DTP-IPV-Hib vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type B disease from the age of 2 months. It is administered by intramuscular injections according to a three or four dose schedule.
Metabolism and pharmacokinetics
The DTP-IPV-Hib vaccine is not metabolized by the cytochrome P450 system.

References

  1. Government bodies
  2. Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015). #1857
  3. Summary of Product Characteristics
  4. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). INFANRIX-IPV+Hib. (Last edition: 19.02. 2015). #1889

Similar drugs
Explore alternative drugs in similar therapeutic classes J07C / J07CA or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙